VistaGen Therapeutics Acquires Worldwide License of Phase 3-Ready CNS Drug Candidate from Pherin Pharmaceuticals Biotech Investing
Advanced Proteome Therapeutics Announces Progress on Antibody-Radioisotope Conjugate Initiative Pharmaceutical Investing
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury Biotech Investing
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress Life Science Investing
U.S. FDA Assigns PDUFA Date to Portola Pharmaceuticals’ Prior Approval Supplement for the Large-Scale Generation 2 Andexxa Process Life Science Investing
FDA Approves Start of Innovative On-Ambulance Phase 2 Clinical Trial for Treatment of Acute Stroke by Diffusion Pharmaceuticals Life Science Investing
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival Biotech Investing
KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug Pharmaceutical Investing
IMV Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA Across Five Solid Tumor Indications Biotech Investing
Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease Biotech Investing
